Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Arcus Biosciences Inc.

    NYSE: RCUS · Real-Time Price · USD
    9.96
    0.33 (3.43%)
    At close: Jun 06, 2025, 3:59 PM
    10.17
    2.06%
    After-hours: Jun 06, 2025, 05:19 PM EDT

    Arcus Biosciences Statistics

    Share Statistics

    Arcus Biosciences has 105.89M shares outstanding. The number of shares has increased by 16.37% in one year.

    Shares Outstanding

    n/a
    		 105.89M

    Shares Change (YoY)

    n/a
    		 16.37%

    Shares Change (QoQ)

    n/a
    		 15.66%

    Owned by Institutions (%)

    n/a
    		 91.8%

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 82

    FTD / Avg. Volume

    n/a
    		 0.01%

    Short Selling Information

    The latest short interest is 9.9M, so 9.35% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 9.9M

    Short % of Shares Out

    n/a
    		 9.35%

    Short % of Float

    n/a
    		 14.34%

    Short Ratio (days to cover)

    n/a
    		 7.78

    Valuation Ratios

    The PE ratio is -4.74 and the forward PE ratio is -2.18. Arcus Biosciences's PEG ratio is 0.19.

    PE Ratio

    n/a
    		 -4.74

    Forward PE

    n/a
    		 -2.18

    PS Ratio

    n/a
    		 5.2

    Forward PS

    n/a
    		 1.2

    PB Ratio

    n/a
    		 2.77

    P/FCF Ratio

    n/a
    		 -7.62

    PEG Ratio

    n/a
    		 0.19
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Arcus Biosciences.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 4.5, with a Debt / Equity ratio of 0.12.

    Current Ratio

    n/a
    		 4.5

    Quick Ratio

    n/a
    		 4.5

    Debt / Equity

    n/a
    		 0.12

    Debt / EBITDA

    n/a
    		 -0.22

    Debt / FCF

    n/a
    		 -0.34

    Interest Coverage

    n/a
    		 -82.5

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $411,483.25

    Profits Per Employee

    n/a
    		 $-451,355.66

    Employee Count

    n/a
    		 627

    Asset Turnover

    n/a
    		 0.22

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 -1M

    Effective Tax Rate

    n/a
    		 0.35%

    Stock Price Statistics

    The stock price has increased by -39.31% in the last 52 weeks. The beta is 0.83, so Arcus Biosciences's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.83

    52-Week Price Change

    n/a
    		 -39.31%

    50-Day Moving Average

    n/a
    		 8.39

    200-Day Moving Average

    n/a
    		 13.14

    Relative Strength Index (RSI)

    n/a
    		 59.07

    Average Volume (20 Days)

    n/a
    		 1,165,519

    Income Statement

    In the last 12 months, Arcus Biosciences had revenue of 258M and earned -283M in profits. Earnings per share was -3.14.

    Revenue

    n/a
    		 258M

    Gross Profit

    n/a
    		 248M

    Operating Income

    n/a
    		 -330M

    Net Income

    n/a
    		 -283M

    EBITDA

    n/a
    		 -268M

    EBIT

    n/a
    		 -279M

    Earnings Per Share (EPS)

    n/a
    		 -3.14
    Full Income Statement

    Balance Sheet

    The company has 150M in cash and 60M in debt, giving a net cash position of 90M.

    Cash & Cash Equivalents

    n/a
    		 150M

    Total Debt

    n/a
    		 60M

    Net Cash

    n/a
    		 90M

    Retained Earnings

    n/a
    		 -1.13B

    Total Assets

    n/a
    		 1.16B

    Working Capital

    n/a
    		 839M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -170M and capital expenditures -6M, giving a free cash flow of -176M.

    Operating Cash Flow

    n/a
    		 -170M

    Capital Expenditures

    n/a
    		 -6M

    Free Cash Flow

    n/a
    		 -176M

    FCF Per Share

    n/a
    		 -1.95
    Full Cash Flow Statement

    Margins

    Gross margin is 96.12%, with operating and profit margins of -127.91% and -109.69%.

    Gross Margin

    n/a
    		 96.12%

    Operating Margin

    n/a
    		 -127.91%

    Pretax Margin

    n/a
    		 -109.69%

    Profit Margin

    n/a
    		 -109.69%

    EBITDA Margin

    n/a
    		 -103.88%

    EBIT Margin

    n/a
    		 -127.91%

    FCF Margin

    n/a
    		 -68.22%

    Dividends & Yields

    RCUS does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for RCUS is $22, which is 128% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $22

    Price Target Difference

    n/a
    		 128%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 9
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -0.69

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist